Jaguar Health Inc. (NASDAQ:JAGX)
Jaguar Health Inc. (NASDAQ:JAGX) traded lower after announcing the approval of its education program, ‘Diarrhea in Foals’ for veterinarians and Veterinary Technicians. Shares of the company fell 6.2% in Tuesday’s trading session to end the day at $0.161 a share.
Diarrhea in Foals AAVSB Approval
The approval by The American Association of Veterinary State Boards (AAVSB) allows the company to offer 1.50 CE credits to each participating veterinarian or veterinary technician.
“Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care. Helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients,” said equine medical consultant Dr. Siobhan McAuliffe, MVB, DACVIM.
Tuesday’s sell-off capped yet another poor run as the stock continues to register lower lows in the market. The stock has lost more than 70% in market value since the start of the year. Jaguar Health is currently trading in a downtrend and close to its 52-week low of $0.18 a share.
Jaguar Health Inc. (NASDAQ:JAGX) is a natural-products pharmaceuticals company focused on developing and commercializing novel gastrointestinal products for human and animal use. The company’s wholly-owned subsidiary develops and commercializes these products for the global marketplace. Mytesi is the company’s lead, FDA-approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.
Jaguar Health Inc. (NASDAQ:JAGX) subsidiary has launched a ‘Keep your pants on’ campaign as it seeks to raise awareness and engage with people living with HIV and Aids. The campaign seeks to provide an easy way of discussing embarrassing topics such as HIV related diarrhea.
Separately Jaguar Health carried out an underwritten public offering of 21.3 million shares of voting common stock in September. The company expects gross proceeds of $4.25 million after pricing the offering at $0.20 a share.
Jaguar Health Inc. (NASDAQ:JAGX) plans to use net proceeds from the offering for commercialization of its lead product Mytesi and for general corporate purposes as well as working capital.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.